Computational Discovery of Novel HSP90AB1 Inhibitor for Hepatocellular Carcinoma Treatment

Strategic Insights -

Scientists at the University of South China have made a groundbreaking discovery in the field of oncology, identifying a promising novel HSP90AB1 inhibitor for hepatocellular carcinoma (HCC) treatment. According to their research, published in the journal Molecular Diversity, the compound 4'-O-methylochnaflavone has shown potential in inhibiting the proliferation of HCC cells and suppressing the expression of HSP90AB1. This breakthrough could lead to the development of more effective treatments for HCC, a global health issue with limited therapeutic efficacy.

Key Takeaways:

  • Researchers from the University of South China have discovered a novel HSP90AB1 inhibitor, 4'-O-methylochnaflavone, for the treatment of hepatocellular carcinoma (HCC).
  • The compound was identified through a multi-step process involving bioinformatic analysis, virtual screening, molecular docking, and experimental validation.
  • In vitro CCK-8 assays demonstrated that 4'-O-methylochnaflavone inhibited Hep3B cell proliferation in a time- and dose-dependent manner.
  • Western blot analysis confirmed hypoxia-induced upregulation of HSP90AB1, which was significantly suppressed by 4'-O-methylochnaflavone.
  • The study's findings suggest that regulating HSPs to improve the immune microenvironment may enhance tumor treatment efficacy.
  • The research has been peer-reviewed and published in the journal Molecular Diversity.

Statistics:

  • 4'-O-methylochnaflavone was identified as a promising HSP90AB1-targeting therapeutic candidate for HCC treatment.
  • The compound demonstrated a significant inhibitory effect on Hep3B cell proliferation, with IC50 values of 2.5+/-0.5 micromolar.
  • Bioinformatic analysis of differentially expressed hypoxia-related immune genes (HRIGs) associated with HCC prognosis revealed HSP90AB1 as the candidate target protein.
  • The interaction between 4'-O-methylochnaflavone and HSP90AB1 was further evaluated by molecular dynamics (MD) simulations and experimental validation using surface plasmon resonance (SPR) assay.

Sources:

  • Computational discovery and validation of 4'-O-methylochnaflavone as a novel HSP90AB1 inhibitor for hepatocellular carcinoma treatment. Molecular Diversity, 2025.
  • NewsRx. Researchers from University of South China Report Findings in Liver Cancer (Computational discovery and validation of 4'-O-methylochnaflavone as a novel HSP90AB1 inhibitor for hepatocellular carcinoma treatment). Cancer Weekly. October 21, 2025; p 1489.